Read by QxMD icon Read

Human Vaccines & Immunotherapeutics

Xin Yao, Lian-Lian Bian, Wei-Wei Lu, Jing-Xin Li, Qun-Ying Mao, Yi-Ping Wang, Fan Gao, Xing Wu, Qiang Ye, Xiu-Ling Li, Feng-Cai Zhu, Zhenglun Liang
Herpangina (HA) and hand, foot, and mouth disease (HFMD) are common infectious diseases caused by human enteroviruses and frequently occurr in young children. Previous published studies have mainly focused on HFMD, while the HA epidemiological and etiological characteristics in mainland China have not been described. From June, 2013 to March, 2014, HA and HFMD patients were monitored in participants from clinical trial of EV-A71 vaccine conducted during 2012-2013. A total of 95 HA patients and 161 HFMD patients were defined...
October 21, 2016: Human Vaccines & Immunotherapeutics
Philippe Hermand, Annick Vandercammen, Emmanuel Mertens, Emmanuel Di Paolo, Vincent Verlant, Philippe Denoël, Fabrice Godfroid
The use of protein antigens able to protect against the majority of Streptococcus pneumoniae serotypes is envisaged as stand-alone and/or complement to the current capsular polysaccharide-based pneumococcal vaccines. Pneumolysin (Ply) is a key virulence factor that is highly conserved in amino acid sequence across pneumococcal serotypes, and therefore may be considered as a vaccine target. However, native Ply cannot be used in vaccines due to its intrinsic cytolytic activity. In the present work a completely, irreversibly detoxified pneumolysin (dPly) has been generated using an optimized formaldehyde treatment...
October 21, 2016: Human Vaccines & Immunotherapeutics
Yanping Li, Rong Cheng Li, Qiang Ye, Changgui Li, You Ping Liu, Xiao Ma, Yanan Li, Hong Zhao, Xiaoling Chen, Deepak Assudani, Naveen Karkada, Htay Htay Han, Olivier Van Der Meeren, Narcisa Mesaros
We conducted three phase III, randomized, open-label, clinical trials assessing the safety, reactogenicity (all studies), immunogenicity (Primary vaccination study) and persistence of immune responses (Booster study) to the combined diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b vaccine (DTPa-IPV/Hib) in Chinese infants and toddlers. In the Pilot study (NCT00964028), 50 infants (randomized 1:1) received three doses of DTPa-IPV/Hib at 2-3-4 (Group A) or 3-4-5 months of age (Group B)...
October 21, 2016: Human Vaccines & Immunotherapeutics
Karen K Yam, Angela Brewer, Virginie Bleau, Édith Beaulieu, Corey P Mallett, Brian J Ward
We investigated the long-term immune profiles of dose-sparing, AS03-adjuvanted vaccines compared to a traditional high-dose, unadjuvated influenza vaccine formulations. BALB/c mice received 2 IM injections of influenza A/Uruguay/716/2007 (H3N2) split vaccine antigen: high-dose (HD) (3 µg hemagglutinin (HA)/dose) or low-dose (LD) formulations (0.03 µg or 0.003 µg HA) with AS03 and were followed to 34 weeks post-boost (pb). We examined serologic responses, spleen and bone marrow (BM) HA-specific antibody-secreting cells (ASCs) by ELISpot, influenza-specific cytokine/chemokine production in re-stimulated splenocytes by multiplex ELISA, and antigen-specific CD4+ T cells that express cytokines (IL-2, IFNγ, TNFa and IL-5) by flow cytometry...
October 21, 2016: Human Vaccines & Immunotherapeutics
Ashleigh A McGirr, Kevin L Schwartz, Upton Allen, Melinda Solomon, Beate Sander
Background Children with cystic fibrosis (CF) are at higher risk of severe respiratory syncytial virus (RSV) infection, which can lead to a decline in lung function. A monoclonal antibody, palivizumab (PMB), effectively prevents RSV hospitalizations; however, the high cost of PMB, approximately C$10,000 per patient per RSV season, limits its widespread use. We assess the cost-effectiveness of PMB prophylaxis in CF children less than 2 years of age from the Canadian healthcare payer's perspective. Methods In 2014, a Markov cohort model of CF disease and infant RSV infections in the Canadian setting was developed based on literature data...
October 21, 2016: Human Vaccines & Immunotherapeutics
Michel de Jesús Aceves-Sánchez, Mario Alberto Flores-Valdez
No abstract text is available yet for this article.
October 20, 2016: Human Vaccines & Immunotherapeutics
Yuxiao Wang, Jingxin Li, Yuemei Hu, Qi Liang, Mingwei Wei, Fengcai Zhu
Ebola virus disease (EVD) has become a great threat to humans across the world in recent years. The 2014 Ebola epidemic in West Africa caused numerous deaths and attracted worldwide attentions. Since no specific drugs and treatments against EVD was available, vaccination was considered as the most promising and effective method of controlling this epidemic. So far, 7 vaccine candidates had been developed and evaluated through clinical trials. Among them, the recombinant vesicular stomatitis virus-based vaccine (rVSV-EBOV) is the most promising candidate, which demonstrated a significant protection against EVD in phase III clinical trial...
October 20, 2016: Human Vaccines & Immunotherapeutics
Melissa B Gilkey, William A Calo, Macary W Marciniak, Noel T Brewer
BACKGROUND: We sought to estimate the national prevalence of HPV vaccine refusal and delay in a population-based sample of parents of adolescents. We also compared parents who refused versus delayed HPV vaccine in terms of their vaccination beliefs and clinical communication preferences. METHODS: In 2014 to 2015, we conducted an online survey of 1,484 U.S. parents who reported on an 11- to 17-year-old child in their household. We used weighted multinomial logistic regression to assess correlates of HPV vaccine refusal and delay...
October 20, 2016: Human Vaccines & Immunotherapeutics
Shu-Ling Hoshi, Masahide Kondo, Ichiro Okubo
Two rotavirus vaccines are currently available in Japan. We estimated the incremental cost-effectiveness ratio (ICER) of routine infant rotavirus immunisation programme without defining which vaccine to be evaluated, which reflects the current deliberation at the Health Science Council in charge of Immunisation and Vaccine established by the Ministry of Health, Labour and Welfare of Japan. Three ICERs were estimated, one from payers' perspective and two from societal perspective depending on the scenarios to uptake vaccines...
October 20, 2016: Human Vaccines & Immunotherapeutics
Megan K Young, Joseph Bertolini, Pushpa Kotharu, Darryl Maher, Allan W Cripps
The effectiveness of passive immunisation post-exposure to measles appears subject to a dose-response effect. New Zealand and the United Kingdom have increased the recommended dose of polyclonal human immunoglobulin for post-exposure prophylaxis within the last decade in response to concerns about decreasing levels of measles antibodies in these products. This study used the plaque-reduction neutralization test (PRNT) to measure the titre of measles-specific antibodies in Australian immunoglobulin products for post-exposure prophylaxis and compared the utility of an enzyme-linked immunosorbent assay (ELISA) to the PRNT in available Australian and international samples: Australian intramuscular (n = 10), Australian intravenous (n = 28), New Zealand intramuscular (n = 2), Hizentra (subcutaneous)(USA) (n = 3), and Privigen (intravenous)(USA) (n = 2)...
October 20, 2016: Human Vaccines & Immunotherapeutics
Christopher A Seid, Kathryn M Jones, Jeroen Pollet, Brian Keegan, Elissa Hudspeth, Molly Hammond, Junfei Wei, C Patrick McAtee, Leroy Versteeg, Amanda Gutierrez, Zhuyun Liu, Bin Zhan, Jonathan L Respress, Ulrich Strych, Maria Elena Bottazzi, Peter J Hotez
A therapeutic vaccine for human Chagas disease is under development by the Sabin Vaccine Institute Product Development Partnership. The aim of the vaccine is to significantly reduce the parasite burden of Trypanosoma cruzi in humans, either as a standalone product or in combination with conventional chemotherapy. Vaccination of mice with Tc24 formulated with monophosphoryl-lipid A (MPLA) adjuvant results in a Th1 skewed immune response with elevated IgG2a and IFNγ levels and a statistically significant decrease in parasitemia following T...
October 13, 2016: Human Vaccines & Immunotherapeutics
Jacek Wysocki, Jerzy Brzostek, Ryszard Konior, Falko G Panzer, Nancy A François, Sudheer M Ravula, Devayani A Kolhe, Yue Song, Ilse Dieussaert, Lode Schuerman, Dorota Borys
To investigate long-term antibody persistence following the administration of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV), we present results of two follow-up studies assessing antibody persistence following two 3+1 schedules up to four (NCT00624819 - Study A) and five years (NCT00891176 - Study B) post-booster vaccination. In Study A, antibody persistence was measured one, two and four years post-booster in children previously primed and boosted with PHiD-CV, or primed with the 7-valent pneumococcal conjugate vaccine (7vCRM) and boosted with either PHiD-CV or 7vCRM...
October 13, 2016: Human Vaccines & Immunotherapeutics
Guillermo M Ruiz-Palacios, Geert Leroux-Roels, Jiri Beran, Jeanne-Marie Devaster, Meral Esen, Odile Launay, Janet E McElhaney, Gerrit A van Essen, Anne Benoit, Carine Claeys, Walthère Dewé, Christelle Durand, Xavier Duval, Ann R Falsey, Gregory Feldman, Florence Galtier, Pierre Gervais, Shinn-Jang Hwang, Shelly McNeil, Jan Hendrik Richardus, Andrew Trofa, Lidia Oostvogels
In this study we describe the immunogenicity results from a subset of older people (N = 5187) who participated in a Phase 3 randomized, observer-blinded trial of AS03-TIV versus TIV (Fluarix™) (, NCT00753272). Participants received one dose of AS03-TIV or TIV in each study year and antibody titers against the vaccine strains were assessed using hemagglutination-inhibition (HI) assay at 21 days and 180 days post-vaccination in each vaccine group in the 2008/09 (Year 1) and 2009/10 (Year 2) influenza seasons...
October 3, 2016: Human Vaccines & Immunotherapeutics
Fabíola Bof de Andrade, Ana Paula Sayuri Sato, Roudom Ferreira Moura, José Leopoldo Ferreira Antunes
This study aimed at assessing the factors associated with vaccine uptake in a representative sample of community-dwelling Brazilian older adults, specifically focusing on differences in socioeconomic factors among the country regions. We conducted a cross-sectional, population-based study, using a probabilistic household sample in 2013. Individuals aged 60 years or more answered a structured questionnaire informing on vaccination status and sociodemographic and behavioral covariates. Associations between variables were evaluated using prevalence ratios estimated by Poisson regression models...
October 3, 2016: Human Vaccines & Immunotherapeutics
Tarun Saluja, Mandeep S Dhingra, Shiv D Sharma, Madhu Gupta, Ritabrata Kundu, Sonali Kar, Ashok K Dutta, Maria D P Silveira, Jai V Singh, Veena G Kamath, Anurag Chaudhary, Venkateswara Rao, Mandyam D Ravi, Kesava Murthy, Rajesh Arumugam, Annick Moureau, Rajendra Prasad, Badri N Patnaik
Rotavirus is the leading cause of severe and dehydrating diarrhea in children aged under 5 years. We undertook this hospital-based surveillance study to examine the possible relationship between the severity of diarrhea and the various G-group rotaviruses circulating in India. Stool samples (n = 2,051) were systematically collected from 4,711 children aged < 5 years admitted with severe acute gastroenteritis to 12 medical school centers from April 2011 to July 2012. Rotavirus testing was undertaken using a commercially available enzyme immunoassay kit for the rotavirus VP6 antigen (Premier Rotaclone Qualitative ELISA)...
September 29, 2016: Human Vaccines & Immunotherapeutics
Guoying Ni, Yuejian Wang, Scott Cummins, Shelley Walton, Kate Mounsey, Xiaosong Liu, Ming Q Wei, Tianfang Wang
Interleukin 10 (IL-10) is a cytokine that is able to downregulate inflammation. Its overexpression is directly associated with the difficulty in the clearance of chronic viral infections, such as chronic hepatitis B, hepatitis C and HIV infection, and infection-related cancer. IL-10 signaling blockade has been proposed as a promising way of clearing chronic viral infection and preventing tumor growth in animal models. Recently, we have reported that peptides with a helical repeating pattern of hydrophobic and hydrophilic residues are able to inhibit IL-10 significantly both in vitro and in vivo (1) ...
September 29, 2016: Human Vaccines & Immunotherapeutics
Chukiat Sirivichayakul, Pornthep Chanthavanich, Kriengsak Limkittikul, Claire-Anne Siegrist, Wassana Wijagkanalan, Pailinrut Chinwangso, Jean Petre, Pham Hong Thai, Mukesh Chauhan, Simonetta Viviani
BACKGROUND: An acellular Pertussis (aP) vaccine containing recombinant genetically detoxified Pertussis Toxin (rPT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) has been developed by BioNet-Asia (BioNet). We present here the results of the first clinical study of this recombinant aP vaccine formulated alone or in combination with tetanus and diphtheria toxoids (TdaP). METHODS: A phase I/II, observer-blind, randomized controlled trial was conducted at Mahidol University in Bangkok, Thailand in healthy adult volunteers aged 18-35 years...
September 29, 2016: Human Vaccines & Immunotherapeutics
Jesús Zacarías Villarreal Pérez, José Manuel Ramírez Aranda, Manuel de la O Cavazos, Michelle de J Zamudio Osuna, José Perales Dávila, María Romelia Ballesteros Elizondo, Marco Vinicio Gómez Meza, Francisco Javier García Elizondo, Azucena M Rodríguez González
Immunization with the tetanus, diphtheria, and pertussis (Tdap) vaccine raises controversies on immunogenicity and possible antibody interference. We performed an experimental, double-blind, parallel group controlled clinical trial to evaluate the safety and immunogenicity of the Tdap vaccine in 204 pregnant women and their children and to determine its interference in antibody production. Pregnant women 18 to 38 years of age with 12 to 24 weeks gestation, a low obstetric risk, and without serious disease were randomly selected...
September 29, 2016: Human Vaccines & Immunotherapeutics
Glen J Nowak, Michael A Cacciatore
There has been significant and growing interest in vaccine hesitancy and confidence in the United States as well as across the globe. While studies have used confidence measures, few studies have provided in-depth assessments and no studies have assessed parents' confidence in vaccines in relationship to other frequently recommended health-related products for young children. This study used a nationally representative sample of 1000 U.S. parents to identify confidence levels for recommended vaccinations, antibiotics, over-the-counter (OTC) medicines, and vitamins for children...
September 28, 2016: Human Vaccines & Immunotherapeutics
Rebecca F Wu, Richard K Zimmerman, Chyongchiou Jeng Lin
BACKGROUND: The human papillomavirus (HPV) vaccine is recommended for male and female recipients aged 9-26 years, and is effective in preventing HPV infection and cancer precursors. However, there is variability in immunogenicity among recipients as measured by anti-HPV geometric mean titers. In this study, we explored the effect of stress level on the immunogenicity of the HPV vaccine among college age males. METHODS: 220 males aged 18-25 years were randomly assigned to 6-month (0, 2, and 6) and 12-month (0, 2, and 12) dosing schedules...
September 28, 2016: Human Vaccines & Immunotherapeutics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"